Equity Profile

TNGX

Tango Therapeutics, Inc.

Health CareBiotechnology$4.3B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of a company's profitability and will show how well Tango is managing its expenses.

$-0.32

Revenue

While no revenue is expected this quarter, any updates on future revenue potential or partnerships could be significant.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

TNGX Q2-2026 Earnings Preview

Context

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. Operating in the health care sector, its work is particularly relevant as the demand for effective cancer treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

In Q1-2026, Tango reported an EPS of $-0.32, matching analyst expectations closely. The stock reacted positively, gaining 8.55% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Tango to report an EPS of $-0.32, indicating continued losses. The lack of revenue is a concern, but the market is watching for any signs of progress in their drug development pipeline.

Bull Case

If Tango can demonstrate advancements in its clinical trials or potential partnerships, it could lead to a more optimistic outlook and a positive stock reaction.

Bear Case

Conversely, if the company fails to provide updates on its drug pipeline or reports worse-than-expected losses, it could lead to a negative reaction from investors.

Key Metrics to Watch

EPS

$-0.32

Earnings per share (EPS) is a key indicator of a company's profitability and will show how well Tango is managing its expenses.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue potential or partnerships could be significant.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Tango provide any updates on its drug development pipeline?

Investors are keen to know if there are any advancements or setbacks that could impact future revenue potential.

How does management plan to address continued losses?

Understanding the company's strategy for managing expenses and achieving profitability is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus is overly focused on short-term losses without considering the long-term potential of Tango's drug pipeline.

Supporting Evidence

The stock has shown resilience with positive reactions in the past despite losses.

Options pricing suggests a lower expected move compared to historical averages, indicating potential undervaluation.

Key Risk

If there are any positive updates on drug trials, it could significantly shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the balance between ongoing losses and any potential for future revenue.

Bull Confirmed If

Positive updates on drug development or partnerships that suggest a path to revenue generation.

Bear Confirmed If

Continued losses without a clear plan for future profitability or updates on drug trials.

Pre-Earnings Positioning

Options Market

Implied Move

±8.57%

Historical Avg

±14.0%

Pricing cheap

The options market is pricing in an 8.57% move in either direction, suggesting uncertainty around the earnings report.

Options are pricing ±8.6% while TNGX has averaged ±14.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.1%

30d HV

93.8%

Calls (1K)P/C Ratio: 1.21Puts (13K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations and raises guidance, history suggests the stock could see an average one-day move of +0.09%, confirming a bullish outlook.

In-Line / Cautious

If the results are in line with expectations, the stock may react cautiously as investors await further details from management.

Miss

If the company misses expectations, history suggests an average one-day move of +5.68%, indicating potential downside pressure.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials for their lead drug candidates.
2Any new partnerships or collaborations that could enhance revenue potential.
3Management's strategy for reducing operational costs.
4Insights into the competitive landscape and how Tango plans to differentiate itself.
5Future guidance on expected timelines for product launches.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of a company's profitability and will show how well Tango is managing its expenses.

$-0.32

Revenue

While no revenue is expected this quarter, any updates on future revenue potential or partnerships could be significant.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

TNGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

In Q1-2026, Tango reported an EPS of $-0.32, matching analyst expectations closely. The stock reacted positively, gaining 8.55% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Tango can demonstrate advancements in its clinical trials or potential partnerships, it could lead to a more optimistic outlook and a positive stock reaction.

Bear Case

Conversely, if the company fails to provide updates on its drug pipeline or reports worse-than-expected losses, it could lead to a negative reaction from investors.

Key Metrics to Watch

EPS

$-0.32

Earnings per share (EPS) is a key indicator of a company's profitability and will show how well Tango is managing its expenses.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue potential or partnerships could be significant.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Tango provide any updates on its drug development pipeline?

Investors are keen to know if there are any advancements or setbacks that could impact future revenue potential.

How does management plan to address continued losses?

Understanding the company's strategy for managing expenses and achieving profitability is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus is overly focused on short-term losses without considering the long-term potential of Tango's drug pipeline.

Supporting Evidence

The stock has shown resilience with positive reactions in the past despite losses.

Options pricing suggests a lower expected move compared to historical averages, indicating potential undervaluation.

Key Risk

If there are any positive updates on drug trials, it could significantly shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the balance between ongoing losses and any potential for future revenue.

Bull Confirmed If

Positive updates on drug development or partnerships that suggest a path to revenue generation.

Bear Confirmed If

Continued losses without a clear plan for future profitability or updates on drug trials.

Pre-Earnings Positioning

Options Market

Implied Move

±8.57%

Historical Avg

±14.0%

Pricing cheap

The options market is pricing in an 8.57% move in either direction, suggesting uncertainty around the earnings report.

Options are pricing ±8.6% while TNGX has averaged ±14.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.1%

30d HV

93.8%

Calls (1K)P/C Ratio: 1.21Puts (13K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations and raises guidance, history suggests the stock could see an average one-day move of +0.09%, confirming a bullish outlook.

In-Line / Cautious

If the results are in line with expectations, the stock may react cautiously as investors await further details from management.

Miss

If the company misses expectations, history suggests an average one-day move of +5.68%, indicating potential downside pressure.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials for their lead drug candidates.
2Any new partnerships or collaborations that could enhance revenue potential.
3Management's strategy for reducing operational costs.
4Insights into the competitive landscape and how Tango plans to differentiate itself.
5Future guidance on expected timelines for product launches.